Source-grounded facts extracted from Immix Biopharma, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Immix Biopharma, Inc. shareholders approved Ratification of Auditors at the 2026-05-22 meeting.
“The stockholders ratified the appointment of Crowe LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The results of the voting for this proposal were as follows: For Against Abstentions Broker Non-Votes 42,276,496 11,526 18,442 —”
Immix Biopharma, Inc. shareholders approved Election of Directors at the 2026-05-22 meeting.
“The stockholders elected each of the individuals listed below to serve as a director of the Company until the next annual meeting of stockholders and until such director’s successor is duly elected and qualified. The results of the voting for this proposal were as follows: For Withheld Broker Non-Votes Ilya Rachman 35,738,887 121,893 6,445,684 Gabriel Morris 34,353,302 1,507,479 6,445,683 Jason Hsu 35,844,812 15,969 6,445,683 Magda Marquet 35,731,188 129,592 6,445,684 Helen C. Adams 35,677,258 183,522 6,445,684 Carey Ng 35,840,860 19,921 6,445,683 Jane Buchan 35,731,346 129,434 6,445,684 Yekaterina Chudnovsky 35,749,420 111,360 6,445,684 Nancy Chang 35,744,455 116,325 6,445,684”
Immix Biopharma, Inc. amended Amendment No. 1 to At The Market Offering Agreement with Citizens JMP Securities, LLC valued at aggregate offering price of up to $100,000,000 in an at the market offering (effective 2026-03-25).
“On March 25, 2026, Immix Biopharma, Inc., a Delaware corporation (the “Company”) and Citizens JMP Securities, LLC entered into Amendment No. 1 (“Amendment No. 1”) to that certain At The Market Offering Agreement, dated June 3, 2025 (the “Sales Agreement”), pursuant to which the Company may offer and sell, from time to time, at its option, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), through Citizens JMP Securities, LLC, as sales agent (the “Sales Agent”), having an aggregate offering price of up to $100,000,000 (the “Shares”) in an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “Securities Act”).”
Immix Biopharma, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC valued at 19,117,646 shares at $5.10 per share and pre-funded warrants to purchase 490,196 shares at $5.09 per (effective 2025-12-07).
“On December 7, 2025, Immix Biopharma, Inc., a Delaware corporation (the “ Company ”), entered into an underwriting agreement (the “ Underwriting Agreement ”) with Morgan Stanley & Co. LLC, as representative of the several underwriters named in Schedule 1 thereto (the “ Underwriters ”), relating to the issuance and sale (the “ Offering ”) of 19,117,646 shares of its common stock, par value $0.0001 per share (the “ Shares ”), and pre-funded warrants to purchase 490,196 shares of its common stock (the “ Pre-Funded Warrants ”).”
Immix Biopharma, Inc. entered into Underwriting Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC valued at $15 million (effective 2024-02-05).
“On February 5, 2024, Immix Biopharma, Inc. (the “Company”) entered into an Underwriting Agreement (the “Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC (the “Underwriter”), relating to an underwritten offering (the “Offering”) of 5,535,055 shares (“Shares”) of common stock of the Company (“Common Stock”).”
Immix Biopharma, Inc. entered into Securities Purchase Agreement with a certain accredited investor valued at approximately $10 million (effective 2023-08-21).
“On August 21, 2023, Immix Biopharma, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with a certain accredited investor (the “Purchaser”), pursuant to which the Company agreed to sell and issue to the Purchaser in a private placement transaction (the “Private Placement”) (i) 3,241,076 shares (the “Shares”) of the Company’s common stock, par value $0.0001 (“Common Stock”), and (ii) pre-funded warrants to purchase 1,913,661 shares of Common Stock (the “Pre-Funded Warrants”).”
Yekaterina Chudnovsky was appointed as Director at Immix Biopharma, Inc..
“Effective August 22, 2023 and in connection with the closing of the Private Placement, the Board of Directors (the “Board”) of the Company appointed Yekaterina Chudnovsky as a member of the Board”
Immix Biopharma, Inc. entered into ATM Sales Agreement with ThinkEquity LLC (effective 2023-07-14).
“On July 14, 2023, Immix Biopharma, Inc. (the “Company”) entered into an ATM Sales Agreement (the “Sales Agreement”) with ThinkEquity LLC (the “Sales Agent”)”
Immix Biopharma, Inc. shareholders approved Approval of Immix Biopharma, Inc. Amended and Restated 2021 Omnibus Equity Incentive Plan at the 2023-06-07 meeting.
“The result of the votes to approve the Amended and Restated 2021 Plan was as follows: For Against Abstain Broker Non-Votes 7,315,768 295,959 10,792 1,919,951”
Immix Biopharma, Inc. shareholders approved Ratification of KMJ Corbin & Company LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-07 meeting.
“The result of the votes to approve KMJ was as follows: For Against Abstain Broker Non-Votes 9,497,865 36,813 7,792 0”
Immix Biopharma, Inc. shareholders approved Election of seven directors at the 2023-06-07 meeting.
“All of the seven nominees for director were elected to serve until the next annual meeting of stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the seven directors were as follows: Directors For Withhold Broker Non-Votes Ilya Rachman 7,600,072 22,447 1,919,951 Gabriel Morris 7,457,001 165,518 1,919,951 Jason Hsu 7,560,452 62,066 1,919,952 Magda Marquet 7,491,766 130,753 1,919,951 Helen C. Adams 7,488,906 133,612 1,919,952 Carey Ng 7,585,080 37,438 1,919,952 Jane Buchan 7,495,642 126,877 1,919,951”
Immix Biopharma, Inc. entered into Sales Agreement with ThinkEquity LLC valued at up to $5,000,000 (effective 2023-03-22).
“On March 22, 2023, Immix Biopharma, Inc. (the “Company”) entered into an ATM Sales Agreement (the “Sales Agreement”) with ThinkEquity LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $5,000,000”
Immix Biopharma, Inc. entered into Purchase Agreements with certain accredited investors valued at approximately $650,000 (effective 2023-01-12).
“On January 12, 2023, Nexcella, Inc. (“Nexcella”), a subsidiary of Immix Biopharma, Inc. (collectively, the “Company”) entered into share purchase agreements (the “Purchase Agreements”) with certain accredited investors for their purchase of an aggregate 100,152 shares of Nexcella’s common stock at a purchase price of $6.49 per share, for gross proceeds of approximately $650,000 (the “Private Placement”).”
Immix Biopharma, Inc. entered into Research and License Agreement with Hadasit Medical Research Services & Development, Ltd. and BIRAD Research and Development Company Ltd. valued at $1,500,000 (effective 2022-12-08).
“On December 8, 2022, Nexcella, Inc. (formerly Immix Biopharma Cell Therapy, Inc.) (“Nexcella”), a wholly-owned subsidiary of Immix Biopharma, Inc. (the “Company”) entered into a Research and License Agreement (the “Agreement”) with Hadasit Medical Research Services & Development, Ltd. and BIRAD Research and Development Company Ltd. (collectively, the “Licensors”)”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.